CN102448466A - 伊奈骨化醇的新治疗应用 - Google Patents

伊奈骨化醇的新治疗应用 Download PDF

Info

Publication number
CN102448466A
CN102448466A CN2010800222064A CN201080022206A CN102448466A CN 102448466 A CN102448466 A CN 102448466A CN 2010800222064 A CN2010800222064 A CN 2010800222064A CN 201080022206 A CN201080022206 A CN 201080022206A CN 102448466 A CN102448466 A CN 102448466A
Authority
CN
China
Prior art keywords
inecalcitol
day
administration
cancer
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800222064A
Other languages
English (en)
Chinese (zh)
Inventor
雷米·德兰索纳
让-弗朗索瓦·杜富尔-拉马蒂尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aton SA
Original Assignee
Hybrigenics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybrigenics SA filed Critical Hybrigenics SA
Publication of CN102448466A publication Critical patent/CN102448466A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN2010800222064A 2009-05-20 2010-05-18 伊奈骨化醇的新治疗应用 Pending CN102448466A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17990609P 2009-05-20 2009-05-20
US61/179,906 2009-05-20
PCT/EP2010/056832 WO2010145903A1 (en) 2009-05-20 2010-05-18 New therapeutical uses of inecalcitol

Publications (1)

Publication Number Publication Date
CN102448466A true CN102448466A (zh) 2012-05-09

Family

ID=42308305

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800222064A Pending CN102448466A (zh) 2009-05-20 2010-05-18 伊奈骨化醇的新治疗应用

Country Status (23)

Country Link
US (1) US8481514B2 (cg-RX-API-DMAC10.html)
EP (1) EP2263677B1 (cg-RX-API-DMAC10.html)
JP (2) JP2012527424A (cg-RX-API-DMAC10.html)
KR (1) KR101845320B1 (cg-RX-API-DMAC10.html)
CN (1) CN102448466A (cg-RX-API-DMAC10.html)
AT (1) ATE505194T1 (cg-RX-API-DMAC10.html)
AU (1) AU2010261967B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI1009056A2 (cg-RX-API-DMAC10.html)
CA (1) CA2762458C (cg-RX-API-DMAC10.html)
DE (1) DE602010000019D1 (cg-RX-API-DMAC10.html)
DK (1) DK2263677T3 (cg-RX-API-DMAC10.html)
ES (1) ES2363070T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20110433T1 (cg-RX-API-DMAC10.html)
IL (1) IL216418A (cg-RX-API-DMAC10.html)
MX (1) MX2011012330A (cg-RX-API-DMAC10.html)
NZ (1) NZ596497A (cg-RX-API-DMAC10.html)
PL (1) PL2263677T3 (cg-RX-API-DMAC10.html)
PT (1) PT2263677E (cg-RX-API-DMAC10.html)
RU (1) RU2571490C2 (cg-RX-API-DMAC10.html)
SG (1) SG176581A1 (cg-RX-API-DMAC10.html)
SI (1) SI2263677T1 (cg-RX-API-DMAC10.html)
UA (1) UA105792C2 (cg-RX-API-DMAC10.html)
WO (1) WO2010145903A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2360145T3 (da) 2010-01-26 2012-07-09 Hybrigenics Sa Hidtil ukendt fremgangsmåde til isomerisering af kondenserede bicykliske strukturer og fremstilling af D-vitaminanaloger, der omfatter disse
EP2407152A1 (en) * 2010-07-15 2012-01-18 Hybrigenics S.A. Formulations of 14-epi-analogues of vitamin D
AU2011278346B2 (en) * 2010-07-15 2016-04-07 Hybrigenics Sa New formulations of 14 - epi -analogues of vitamin D
US20120015913A1 (en) 2010-07-15 2012-01-19 Delansorne Remi Formulations of 14-EPI-Analogues of Vitamin D
WO2015193480A1 (en) * 2014-06-19 2015-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Composition comprising a combination of dna methylation inhibitor and a vitamin d receptor agonist for the treatment of drug resistant cancer or for the prevention of tumor relapse
SG11201809501PA (en) 2016-06-06 2018-12-28 Celgene Corp Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
JP2020143008A (ja) * 2019-03-05 2020-09-10 達也 楠堂 新規褐色脂肪細胞分化誘導剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1130899A (zh) * 1993-07-09 1996-09-11 桑拉米克斯实验公司 维生素d的新型结构类似物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
GB0305332D0 (en) * 2003-03-10 2003-04-09 Leuven K U Res & Dev Biological evaluation of novel vitamin D analogues
CA2580962A1 (en) * 2004-09-24 2006-04-06 Bioxell S.P.A. 20-cycloalkyl,26,27-alkyl/haloalkyl vitamin d3 compounds and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1130899A (zh) * 1993-07-09 1996-09-11 桑拉米克斯实验公司 维生素d的新型结构类似物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GUY EELEN等: "Superagonistic Action of 14-epi-Analogs of 1,25-Dihydroxyvitamin D Explained by Vitamin D Receptor-Coactivator Interaction", 《MOLECULAR PHARMACOLOGY》, vol. 67, no. 5, 31 December 2005 (2005-12-31), pages 1566 - 1573, XP002592441, DOI: doi:10.1124/mol.104.008730 *
LIEVE VERLINDEN等: "Two Novel 14-Epi-Analogues of 1,25-Dihydroxyvitamin D3 Inhibit the Growth of Human Breast Cancer Cells in Vitro and in Vivo", 《CANCER RESEARCH》, vol. 60, 15 May 2000 (2000-05-15), pages 2673 - 2679, XP002592442 *
无: "Promising Interim Results From Hybrigenics Inecalcitol Phase II In Combination With Taxotere(R) For Hormone-Refractory Prostate Cancer", 《MEDICAL NEWS TODAY》, 19 April 2009 (2009-04-19), pages 1 - 2 *

Also Published As

Publication number Publication date
IL216418A0 (en) 2012-02-29
SI2263677T1 (sl) 2011-07-29
UA105792C2 (uk) 2014-06-25
EP2263677B1 (en) 2011-04-13
RU2011151854A (ru) 2013-06-27
RU2571490C2 (ru) 2015-12-20
JP2016179994A (ja) 2016-10-13
KR20120017075A (ko) 2012-02-27
EP2263677A1 (en) 2010-12-22
SG176581A1 (en) 2012-01-30
PL2263677T3 (pl) 2011-09-30
US20110015276A1 (en) 2011-01-20
DE602010000019D1 (de) 2011-05-26
JP2012527424A (ja) 2012-11-08
AU2010261967B2 (en) 2016-03-03
ES2363070T3 (es) 2011-07-19
WO2010145903A1 (en) 2010-12-23
MX2011012330A (es) 2011-12-16
ATE505194T1 (de) 2011-04-15
AU2010261967A1 (en) 2011-12-08
DK2263677T3 (da) 2011-06-06
CA2762458A1 (en) 2010-12-23
HRP20110433T1 (hr) 2011-07-31
US8481514B2 (en) 2013-07-09
NZ596497A (en) 2013-05-31
KR101845320B1 (ko) 2018-04-04
PT2263677E (pt) 2011-06-01
BRPI1009056A2 (pt) 2020-06-02
CA2762458C (en) 2018-08-28
IL216418A (en) 2015-09-24

Similar Documents

Publication Publication Date Title
JP2016179994A (ja) イネカルシトールの新しい治療的使用
JP7432069B2 (ja) ２５－ヒドロキシビタミンｄを用いる補助的療法及びそのための物品
US9737540B2 (en) Combination treatment of cancer
JP2025016586A (ja) ２５－ヒドロキシビタミンｄを用いる補助的療法
JP7382432B2 (ja) ビタミンｄ治療法
KR20040061000A (ko) 활성 비타민 ｄ 유사체를 사용하는 과다증식성 질환의 치료
AU2004220622A1 (en) Method of treating and preventing hyperparathyroidism with vitamin D2 or D4 compounds
CN101848708A (zh) 皮质类固醇用于治疗埃坡霉素或埃坡霉素衍生物诱导的腹泻
EP2407155B1 (en) Formulations of inecalcitol
CN100386083C (zh) 用维生素d类化合物制备治疗骨髓发育不良综合症药物的方法
JP5792322B2 (ja) ビタミンｄおよびメトホルミン含有医薬組成物
UA110211C2 (uk) Нові склади 14-eпi-аналогів вітаміну d
HK40031634B (en) Medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis
US20050239756A1 (en) Methods of treating various vitamin D metabolism conditions with 1alpha-hydroxyvitamin D2
JPH11116501A (ja) 骨吸収関連疾患治療剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20120509

RJ01 Rejection of invention patent application after publication